SARS-CoV-2 intra-host evolution during acute infection in COVID-19 patients
Frontiers in Microbiology · 28.04.2026 · 17
DOI: 10.3389/fmicb.2026.1794039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 28.04.2026. Verfasst von Carla Della Ventura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The intra-host evolution represents the mechanism causing the continued emergence of new, highly divergent SARS-CoV-2 variants. The aim of this work was to investigate the intra-host evolution to ass the conditions associated with the acquisition of new viral mutations.
Methods
Whole genome sequences of 58 cases of COVID-19 with 2 or more consecutive positive swabs were analyzed. Variant calling and minority mutations analysis were performed using Nextclade and Stanford Coronavirus Antiviral & Resistance Database.
Results
Fifty-seven subjects were hospitalized for a median of 23 days, and 12 died (20.7%) after a median of 25 days. 78.9% (45/58) were vaccinated and 22.4% (13/58) received more than one treatment for SARS-CoV-2 infection. None reported previous SARS-CoV-2 infection. Negativization period showed longer intervals in BQ.1 infections (38.5 days) and shorter in BA.1 infections (16.5 days). Comparing the first positive swab to the second swab (T1 and T2), 36.7 and 38.8% decreased/increased number of mutations while 24.5% maintained the same number. Subjects with constant numbers of mutations maintained the same pattern while 57% of the acquisitions and losses were confirmed compared to the previous timepoint. Comparing the second to the third swab (T2 and T3), 66.7 and 33.3% of strains increased or maintained the same number of mutations, respectively. 75% of subjects with constant number of mutations maintained the same pattern. 63% of the acquisitions were confirmed. In T1 vs. T2 the acquisitions were prevalent in the S gene and the losses in ORF1a, in T2 vs. T3 the opposite was observed. Subjects with cardiovascular disease showed a significantly higher acquisition of mutations over time.
Discussion
Our data suggested a mechanism with different steps of fitness selection of SARS-CoV-2 mutations and highlighted the presence of highly divergent intra-patient variants within 3 weeks of infection, regardless of treatment, confirming data from other studies showing that new viral variants can also emerge during acute infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
- III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.
- National PhD Programme in One Health Approaches to Infectious Diseases and Life Science Research, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.
Zitieren
APA
Della Ventura, C., Bergna, A., Ciubotariu, C. L., Liturri, M., Conflitti, C., Corbellino, M., Antinori, S., Riva, A., Zehender, G., & Lai, A. (2026). SARS-CoV-2 intra-host evolution during acute infection in COVID-19 patients. Frontiers in Microbiology, 17. https://doi.org/10.3389/fmicb.2026.1794039
Vancouver
Della Ventura C, Bergna A, Ciubotariu CL, Liturri M, Conflitti C, Corbellino M, et al. SARS-CoV-2 intra-host evolution during acute infection in COVID-19 patients. Frontiers in Microbiology. 2026;17. doi:10.3389/fmicb.2026.1794039
BibTeX
@article{DellaVentura2026,
author = {Della Ventura, Carla and Bergna, Annalisa and Ciubotariu, Cosmin Lucian and Liturri, Mirko and Conflitti, Claudia and Corbellino, Mario and Antinori, Spinello and Riva, Agostino and Zehender, Gianguglielmo and Lai, Alessia},
title = {SARS-CoV-2 intra-host evolution during acute infection in COVID-19 patients},
journal = {Frontiers in Microbiology},
year = {2026},
volume = {17},
doi = {10.3389/fmicb.2026.1794039}
}
EUVIMED